Significados de terlipressin en inglés

Adverse effects are common with terlipressin and need to be monitored strictly.

However, how terlipressin exerts its effect on the renal artery is unknown.

There is documented mortality benefit with terlipressin therapy in HRS and AVB.

Our review warrants a fresh perspective on the efficacy and safety of terlipressin.

However, terlipressin is not yet recommended for such indications.

Our centre provides outpatient terlipressin for weeks to months as a bridge to liver transplant.

Conclusions: Treatment with terlipressin and albumin improves renal function in cirrhotic patients with type 1 HRS.

We describe, for the first time, the impact of outpatient terlipressin on nutritional and muscle parameters.

The combination of terlipressin and albumin is efficacious in the reversal of HRS and is used worldwide.

In conclusion, terlipressin has stood the test of time with expanding indications and clear prerequisites for clinical use.

Median cumulative terlipressin dosage and treatment duration were 20 mg and 5 days, respectively.

The effects of terlipressin on systemic, hepatic and renal hemodynamics were observed similarly in patients with and without ascites.

With cumulative evidence supporting the use in cirrhosis, terlipressin has been recommended for the management of HRS and AVB.

However, owing to the safety concerns, terlipressin was not approved by food and drug administration (FDA) until now.

The aim of the present study was to assess the effects of terlipressin on systemic, hepatic and renal hemodynamics in cirrhosis.

Patients who responded to terlipressin and albumin had only a decrease in TNF-a and RANTES after treatment without changes in other cytokines.